Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
7 employees
Co-D Therapeutics: A preclinical biopharmaceutical firm innovating safe, first-in-class cancer nanomedicines.
HQ
Founded
2012
Co-D Therapeutics, Inc. is a preclinical-stage biopharmaceutical company founded in Madison, Wisconsin. The company's core mission is to develop innovative, first-in-class combination nanomedicines with high safety profiles to treat cancer. Utilizing advanced polymeric micelle technology, Co-D aims to enhance drug delivery to solid tumors. Their primary product, Triolimus, is a nanomedicine that combines paclitaxel, rapamycin, and 17-AAG for effective combination cancer therapy. Co-D Therapeutics is focused on establishing strategic partnerships to advance their nanomedicine programs.
Notable affiliated individuals include key researchers and scientists specializing in oncology and nanotechnology. Co-D Therapeutics has garnered attention from investors interested in groundbreaking cancer treatments. Among its key achievements is the development of Triolimus, which represents a significant advancement in combination cancer therapy. The company's innovative approach has the potential to significantly impact cancer treatment by improving drug delivery and efficacy, ultimately aiming to enhance patient outcomes.
Operating Status
Active
Main Product(s)
Cancer Therapy, Nanomedicines
Technology
Nanotechnology
Tags
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Americas
When was Co-D Therapeutics founded?
Co-D Therapeutics was founded in 2012.
Where is Co-D Therapeutics's headquarters located?
Co-D Therapeutics's headquarters is located in Madison, US.
How many employees does Co-D Therapeutics have?
Co-D Therapeutics has 7 employees as of Feb 5, 2024.
How much has Co-D Therapeutics raised to-date?
As of July 05, 2023, Co-D Therapeutics has raised a total of $145k (USD) since Sep 1, 2018.
Add Comparison
Total Raised to Date
$145k
USD
Last Update Sep 1, 2018
Current Employees
7
Last updated: Feb 5, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts